[CPIX] Cumberland Pharmaceuticals Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 75.75 M

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 5.42 Change: 0.02 (0.28%)
Ext. hours: Change: 0 (0%)

chart CPIX

Refresh chart

Strongest Trends Summary For CPIX

CPIX is in the long-term down -30% below S&P in 2 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing branded prescription products for the hospital acute care and gastroenterology markets in the United States. The company?s principal products comprise Acetadote, an intravenous formulation of N-acetylcysteine indicated for the treatment of acetaminophen poisoning; Caldolor, an intravenous formulation of ibuprofen for the treatment of pain and fever; and Kristalose, a prescription laxative administered orally for the treatment of constipation. Its products also include Omeclamox-Pak, a triple therapy combination medication for the treatment of Helicobacter pylori infection and duodenal ulcer disease; and Hepatoren injection, which is in Phase II clinical development for the treatment of hepatorenal syndrome. The company markets and sells its products through sales representatives and managers. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tenne

Fundamental Ratios
Shares Outstanding16.22 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -10.9% Sales Growth - Q/Q-6.88% P/E
P/E To EPS Growth P/S2.02 P/BV0.95 Price/Cash Per Share1.43
Price/Free Cash Flow11.6 ROA2.37% ROE2.75% ROI
Current Ratio5.68 Quick Ratio5.29 Long Term Debt/Equity Debt Ratio0.15
Gross Margin86.23% Operating Margin8.41% Net Profit Margin5.82% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-1.68 M Cash From Investing Activities-1.17 M Cash From Operating Activities2.03 M Gross Profit7.52 M
Net Profit50 K Operating Profit Total Assets92.19 M Total Current Assets67.55 M
Total Current Liabilities11.89 M Total Debt Total Liabilities12.82 M Total Revenue8.69 M
Technical Data
High 52 week7 Low 52 week5.06 Last close5.62 Last change-1.58%
RSI35.49 Average true range0.29 Beta0.53 Volume2.51 K
Simple moving average 20 days-5.27% Simple moving average 50 days-3.35% Simple moving average 200 days-4.57%
Performance Data
Performance Week-4.58% Performance Month-1.4% Performance Quart0.96% Performance Half-0.18%
Performance Year-12.87% Performance Year-to-date-6.8% Volatility daily2.69% Volatility weekly6.01%
Volatility monthly12.32% Volatility yearly42.66% Relative Volume74.79% Average Volume8.99 K
New High New Low


2019-06-04 10:08:02 | The Zacks Analyst Blog Highlights: Flexible Solutions International, Qiwi, Cumberland Pharmaceuticals, CECO Environmental and Entravision Communications

2019-06-04 09:30:01 | Has Cumberland Pharmaceuticals CPIX Outpaced Other Medical Stocks This Year?

2019-06-04 08:39:12 | Nektar NKTR in Focus: Stock Moves 8.8% Higher

2019-06-03 08:31:12 | 5 Stocks That Survived May's Market Mayhem

2019-05-23 09:11:01 | New Strong Buy Stocks for May 23rd

2019-05-23 09:00:01 | Cumberland CPIX Upgraded to Strong Buy: Here's What You Should Know

2019-05-17 08:45:12 | Is Cumberland CPIX a Solid Growth Stock? 3 Reasons to Think " Yes "

2019-05-15 09:35:00 | Cumberland Pharmaceuticals Signs Exclusive Licensing Agreement For Distribution In China

2019-05-14 21:04:40 | Edited Transcript of CPIX earnings conference call or presentation 14-May-19 8:30pm GMT

2019-05-14 17:45:09 | Cumberland Pharmaceuticals CPIX Q1 Earnings and Revenues Beat Estimates

2019-05-14 16:41:34 | Cumberland: 1Q Earnings Snapshot

2019-05-14 16:05:00 | Nashville health care company's strategic review leads it to China

2019-05-14 16:05:00 | Cumberland Pharmaceuticals Reports 38% Revenue Growth In The First Quarter

2019-05-08 17:45:09 | Cumberland Pharmaceuticals CPIX Gains As Market Dips: What You Should Know

2019-05-07 10:30:02 | Analysts Estimate Cumberland Pharmaceuticals CPIX to Report a Decline in Earnings: What to Look Out for

2019-05-07 09:35:00 | Cumberland Pharmaceuticals To Announce First Quarter 2019 Financial Results

2019-05-07 07:53:11 | What's in Cards for Cumberland CPIX This Earnings Season?

2019-05-02 17:45:09 | Cumberland Pharmaceuticals CPIX Dips More Than Broader Markets: What You Should Know

2019-04-25 17:45:09 | Cumberland Pharmaceuticals CPIX Dips More Than Broader Markets: What You Should Know

2019-04-22 15:27:27 | The Cumberland Pharmaceuticals NASDAQ:CPIX Share Price Is Up 31% And Shareholders Are Holding On

2019-03-29 10:42:00 | Cumberland Pharmaceuticals Announces Strategic Review

2019-03-12 07:48:04 | Cumberland Pharmaceuticals Inc CPIX Files 10-K for the Fiscal Year Ended on December 31, 2018

2019-03-06 13:11:33 | Is Cumberland Pharmaceuticals Inc.’s NASDAQ:CPIX CEO Being Overpaid?

2019-02-27 17:49:45 | Edited Transcript of CPIX earnings conference call or presentation 26-Feb-19 9:30pm GMT

2019-02-26 16:05:00 | Cumberland Pharmaceuticals Reports Fourth Quarter Revenue Growth Of 16%

2019-02-26 14:30:00 | Cumberland Pharmaceuticals Inc. to Host Earnings Call

2019-02-19 16:05:00 | Cumberland Pharmaceuticals To Announce Fourth Quarter And Annual 2018 Financial Results

2019-01-30 07:44:05 | The Boss: You can find Cumberland Pharmaceuticals' A.J. Kazimi courtside

2019-01-25 07:01:12 | Cumberland Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

2019-01-23 08:47:58 | With $500M in reserve, biotech cuts 49 jobs to focus on maturing drug pipeline

2019-01-11 10:32:03 | Ocular OCUL Submits an sNDA for Eye Pain Drug Dextenza

2019-01-03 10:26:03 | Flexion Starts Phase III Enrollment on Zilretta for Hip OA

2018-12-19 15:09:08 | Small Drug Stocks Near-Term Outlook Positive, Despite Headwinds

2018-12-11 14:26:59 | Is Cumberland Pharmaceuticals Inc.’s NASDAQ:CPIX Balance Sheet A Threat To Its Future?

2018-12-03 08:46:22 | U.S. and China set to finalize a trade deal in the next three months

2018-11-14 07:21:57 | Edited Transcript of CPIX earnings conference call or presentation 13-Nov-18 9:30pm GMT

2018-11-13 20:10:01 | Cumberland Pharmaceuticals CPIX Reports Q3 Loss, Misses Revenue Estimates

2018-11-13 19:01:44 | Cumberland: 3Q Earnings Snapshot

2018-11-13 16:05:00 | Cumberland Pharmaceuticals Reports Third Quarter 2018 Financial Results

2018-11-07 16:05:00 | Cumberland Pharmaceuticals To Announce Third Quarter 2018 Financial Results

2018-11-06 14:23:13 | Nashville pharma company pays $25M for drug brand

2018-11-06 08:30:00 | Theravance Biopharma Announces Sale of VIBATIV® telavancin to Cumberland Pharmaceuticals

2018-11-06 08:30:00 | Cumberland Pharmaceuticals To Acquire VIBATIV®

2018-09-27 15:27:42 | The Cumberland Pharmaceuticals Inc NASDAQ:CPIX Ownership Structure Could Be Important

2018-09-27 09:00:00 | Newly Published Data Demonstrates Amifostine Delayed The Onset Of Acute Esophagitis For Small Cell Lung Cancer Patients

2018-09-24 10:00:00 | Cumberland Pharmaceuticals Announces Senior Music Industry Executive Joins Its Board Of Directors

2018-09-21 12:18:20 | Exclusive: Music industry giant joins public health care company's board

2018-08-14 19:40:29 | Edited Transcript of CPIX earnings conference call or presentation 14-Aug-18 8:30pm GMT

2018-08-14 16:57:24 | Cumberland: 2Q Earnings Snapshot

2018-08-14 16:05:00 | Cumberland Pharmaceuticals Reports Second Quarter 2018 Financial Results